Joe T.R. Clarke - Concepedia

Author

Joe T.R. Clarke

Also Known As

J CLARKE, J T Clarke, J T R Clarke, J. Clarke, J. T R Clarke, J. T. Clarke, J. T. R. Clarke, J.T. CLARKE, J.T.R Clarke, J.T.R. Clarke

107

Publications

6.3K

Citations

H-Index

128

Concepts

All Affiliations

Hospital for Sick Children University of Toronto SickKids Foundation Johannes Gutenberg University Mainz Centre Hospitalier Universitaire de Sherbrooke

About

Joe T.R. Clarke is an author at Hospital for Sick Children specializing in medicine, pathology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	36	2.5K
2	Public Health	5	5	324
3	Natural Sciences	3	3	245
4	Health Sciences	2	2	118
5	Social Sciences	1	1	28

Joe T.R. Clarke

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Heteroplasmic mtDNA mutation (T----G) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high. Y. Tatuch, John Christodoulou, Annette Feigenbaum, PubMed	1992	484
Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease Gustavo Maegawa, Michael B. Tropak, Justin Buttner, Journal of Biological Chemistry	2009	328
The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I Gregory M. Pastores, Pamela Arn, Michael Beck, Molecular Genetics and Metabolism Mucopolysaccharidosis TypeMedicineInternational HealthPathologyDiagnosis	2007	203
Initial report from the Hunter Outcome Survey J. E. Wraith, Michael Beck, Roberto Giugliani, Genetics in Medicine	2008	186
Pyrimethamine as a Potential Pharmacological Chaperone for Late-onset Forms of GM2 Gangliosidosis Gustavo Maegawa, Michael B. Tropak, Justin Buttner, Journal of Biological Chemistry Late-onset FormsAntiparasitic AgentGlycobiologyPharmacotherapyInhibitory Activity	2007	176
Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS) Simon Jones, Zsuzsanna Almássy, Michael Beck, Journal of Inherited Metabolic Disease	2009	175
Enzyme-Replacement Therapy With Agalsidase Alfa in Children With Fabry Disease Markus Ries, Joe T.R. Clarke, Catharina Whybra, PEDIATRICS	2006	162
Agalsidase Alfa and Kidney Dysfunction in Fabry Disease Michael L. West, Kathy Nicholls, Atul Mehta, Journal of the American Society of Nephrology Glomerular DiseasePathologyGlomerulonephritisFabry DiseaseRenal Function	2009	160
Treatment of Familial Hypercholesterolemia in Children and Adolescents: Effect of Lovastatin Marie Lambert, Paul-J. Lupien, Claude Gagné, PEDIATRICS	1996	159
Genomic Rearrangements Resulting in PLP1 Deletion Occur by Nonhomologous End Joining and Cause Different Dysmyelinating Phenotypes in Males and Females Ken Inoue, Hitoshi Osaka, Virginia C. Thurston, The American Journal of Human Genetics Developmental BiologyMendelian DisorderGenetic DisorderGeneticsGenomic Rearrangements	2002	159

Page 1